InfiniSeqTM Covid-19 Whole Genome Sequencing kit

Sequencing the SARS-CoV-2 genome from Covid19 positive samples is an important tool for variant surveillance and new strain identification. “Infiniseq Covid19 Whole Genome Sequencing kit” yields a Covid-19 Whole Genome Sequencing library using the Infiniseq targeted sequencing technology

The assay includes the Infiniseq SARS-CoV-2 probes, Infiniseq reagents, and InfiniSeq dual indexes required for the creation of indexed Illumina libraries directly from cDNA, derived from SARS-CoV-2 RNA samples. The Infiniseq kit supports up to 384 multiplexed samples in a NextSeq550 run (400M reads) and up to 1536 multiplexed samples in a Novaseq6000 flow cell.

Easily installed on prem/cloud based analysis outputs the consensus sequence and variants compared to a reference sequence of choice. Consensus sequences can be analyzed for strain and lineage annotation using open software tools and can be uploaded to NCBI/GISAID databases.

✔ High-quality libraries. Full genome coverage validated with SARS-CoV-2 Twist
synthetic RNA. More than 95% coverage at X30 using clinical samples.
✔ Simplest and fastest workflow. Only 4 hands-on steps and 3.5 hours from cDNA to an NGS library, ramping any lab’s throughput without additional instrumentation cost. Less than a working day from RNA to NGS.
✔ Automation friendly.
✔ Universality. Compatible with all Covid-19 variants present to date.
✔ Diverce sequencing options. Supports both single and paired-end 150 bp sequencing.
✔ One pot reaction. No internal purification steps are required. Reduction in
consumables consumption and lower chance for cross contamination.
✔ Fits any lab. The only required equipment is a standard thermal cycler.
✔ Easy implementation.
✔ Lowest cost. Support high throughput/whole population pricing.
✔ Made in Israel. By Sequentify, a Weizmann Institute company.